Belgium has decided to provide emergency assistance to Tunisia, following a request transmitted by this country through the European Mechanism of Civil Protection, in the context of the fight against COVID-19. Tunisia is currently facing a serious deterioration of its health situation and a sharp increase in hospitalizations. The country has informed its European partners of specific needs to help it cope with this situation, including in terms of vaccines. The vaccination rate remains very low in the country and the authorities are trying to accelerate the vaccination campaign.
Belgium's assistance will consist of :
150,000 doses of vaccine (AstraZeneca);
Intensive care drugs (Cisatracurium 10mg - 6980 vials and Midazolam 50mg - 9980 vials) from the stock of the FPS Public Health;
Medical equipment for intensive care and personal protective equipment (including gloves and masks) from the stock of the Defense.
The vaccines come from the stock of the FPS Public Health constituted in the framework of the national vaccination campaign in Belgium. The vaccination campaign is progressing very well in Belgium. This stock of AstraZeneca vaccines was no longer to be used in the framework of the campaign, following a reorientation of the campaign.
This aid will leave this Thursday, July 22 from Belgium.
Belgium wishes to express its solidarity with the Tunisian authorities and population, who are facing a difficult phase of the COVID-19 pandemic. International solidarity in the context of such a pandemic is all the more crucial as none of us is safe until we are all safe. Belgium also sees this contribution as an encouragement to the vaccination based on its own experience and the positive effects of vaccination on the health situation.
Distributed by APO Group on behalf of Kingdom of Belgium - Foreign Affairs, Foreign Trade and Development Cooperation.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
